Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04575740
Other study ID # PhenOSA
Secondary ID 1R01HL153874
Status Recruiting
Phase N/A
First received
Last updated
Start date September 10, 2020
Est. completion date June 30, 2024

Study information

Verified date December 2021
Source Brigham and Women's Hospital
Contact Nkiru G Ujomu
Phone 617-732-8976
Email nujomu@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obstructive sleep apnea (OSA) is a highly prevalent disorder with adverse neurocognitive and cardio-metabolic outcomes. Continuous positive airway pressure (CPAP) is the gold standard therapeutic option to treat airway obstructions during sleep and thus, prevent its adverse cardiovascular and neurocognitive outcomes. Previous clinical trials, however, have largely failed to show a consistent impact of CPAP on these health outcomes. One of the main limitations of these trials may be the inadequate characterization of OSA and its acute physiological consequences. By characterizing OSA based on the "apnea-hypopnea index (AHI)", there is a potential risk of negative results. In this trial, the investigators intend to tackle this issue, by better characterization of OSA-related physiological consequences during sleep using physiologically driven metrics to capture the burden of OSA-related hypoxemia ("hypoxic burden"), autonomic response ("heart rate burden"), and sleep fragmentation ("arousal burden").


Recruitment information / eligibility

Status Recruiting
Enrollment 158
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion criteria: - Adults aged 21-80 years. - Participants with a previous diagnosis of moderate to severe obstructive sleep will be eligible to enroll and attend the baseline study. Patients with a total apnea-hypopnea index greater than 15 events/hr on the baseline study will be eligible for further participation. Exclusion criteria: - Current treatment for obstructive sleep apnea (including CPAP, oral appliances, supplemental oxygen). Patients must be untreated prior to the baseline visit. - Use of medications that might depress respiration (including opioids, barbiturates, benzodiazepines, and Z drugs, including zolpidem, zopiclone, eszopiclone, and zaleplon). - Active use of non-prescription opioids (e.g., cocaine, methamphetamine) - Uncontrolled medical problem or major organ system disease, which, in the opinion of the investigators (PI and Co-Is), would interfere with the evaluation of the subject (e.g., uncontrolled hypertension, unstable coronary heart disease, etc.). - History of congestive heart failure, renal insufficiency, systemic neurological condition that could affect respiration. - Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: - central sleep apnea (>50% of respiratory events scored as central), - chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions. - Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias. - Patients unable or unwilling to use CPAP. - Insomnia or insufficient sleep (self-reported inability to sleep >6 hrs night). - Pregnancy (women)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PAP
Positive airway pressure to treat sleep apnea

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Brigham and Women's Hospital National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline flow-mediated vasodilation at 12 weeks Flow mediated vasodilation is studied using high resolution ultrasound of the artery. 12 weeks
Primary Change from baseline 24-hour mean systolic blood pressure at 12 weeks Mean systolic blood pressure over a 24-hour period is measured using an ambulatory blood pressure monitor. 12 weeks
Primary Change from baseline Epworth Sleepiness Scale (ESS) at 12 weeks Self-reported sleepiness measured using the Epworth Sleepiness Scale (units on a scale). Values range from 0-24; higher values indicate greater sleepiness. 12 weeks
Secondary Change from baseline F2-Isoprostane/Creatinine Ratio at 12 weeks F2-Isoprostane/Creatinine Ratio, a measure of oxidative stress, is calculated from urine sample. 12 weeks
Secondary Change from baseline Albumin/Creatinine Ratio at 12 weeks Urinary Albumin/Creatinine Ratio is calculated from urine samples. 12 weeks
Secondary Change from baseline Albumin without Creatinine at 12 weeks Urinary Albumin is calculated from urine samples. 12 weeks
Secondary Change from baseline Oxidized low-density lipoprotein (LDL) at 12 weeks Oxidized low-density lipoprotein measurements are calculated through fasting phlebotomy. 12 weeks
Secondary Change from baseline N-terminal pro b-type natriuretic peptide (NT-proBNP) at 12 weeks N-terminal pro b-type natriuretic peptide (NT-proBNP) measurements are calculated through fasting phlebotomy. 12 weeks
Secondary Change from baseline Hemoglobin A1c (HbA1c) at 12 weeks Hemoglobin A1c (HbA1c) measurements are calculated through fasting phlebotomy. 12 weeks
Secondary Change from baseline Plasminogen Activator Inhibitor-1 at 12 weeks Plasminogen activator inhibitor type 1 (PAI-1) measurements are calculated through fasting phlebotomy. 12 weeks
Secondary Change from baseline Fibrinogen Antigen at 12 weeks Fibrinogen Antigen measurements are calculated through fasting phlebotomy. High values indicate inflammation and increased risk of atherosclerosis. 12 weeks
Secondary Change from baseline Glucose at 12 weeks Blood glucose measurements are calculated through fasting phlebotomy 12 weeks
Secondary Change from baseline high sensitivity C-Reactive Protein (hs-CRP) at 12 weeks C-reactive protein measurements are calculated from blood samples collected through fasting phlebotomy. 12 weeks
Secondary Change from baseline Interleukin-6 (IL-6) at 12 weeks IL-6 is calculated from blood samples collected through fasting phlebotomy 12 weeks
Secondary Change from baseline Creatinine at 12 weeks Creatinine is calculated from blood samples collected through fasting phlebotomy 12 weeks
Secondary Change from baseline Cystanin C with eGFR at 12 weeks Cystanin C with eGFR is calculated from blood samples collected through fasting phlebotomy 12 weeks
Secondary Change from baseline lipid panel at 12 weeks Lipid panel measurements are calculated from blood samples collected through fasting phlebotomy. 12 weeks
Secondary Change from baseline 24-hour mean diastolic blood pressure at 12 weeks Mean diastolic blood pressure over a 24-hour period is measured using an ambulatory blood pressure monitor. 12 weeks
Secondary Change from baseline 24-hour mean blood pressure at 12 weeks Mean arterial blood pressure over a 24-hour period is measured using an ambulatory blood pressure monitor. 12 weeks
Secondary Change from baseline nocturnal mean systolic blood pressure at 12 weeks Mean systolic blood pressure during sleep is measured using an ambulatory blood pressure monitor. 12 weeks
Secondary Change from baseline nocturnal mean diastolic blood pressure at 12 weeks Mean diastolic blood pressure during sleep is measured using an ambulatory blood pressure monitor. 12 weeks
Secondary Change from baseline nocturnal mean blood pressure at 12 weeks Mean arterial blood pressure during sleep is measured using an ambulatory blood pressure monitor. 12 weeks
Secondary Change from baseline Psychomotor Vigilance Task reaction time at 12 weeks 3-minute Psychomotor Vigilance Tasks will be done to quantify the speed with which subjects respond to a visual stimulus. 12 weeks
Secondary Change from baseline Psychomotor Vigilance Task lapses per test at 12 weeks 3-minute Psychomotor Vigilance Tasks will be done to quantify the speed with which subjects respond to a visual stimulus. 12 weeks
Secondary Change from baseline Functional Outcome of Sleep Questionnaire (FOSQ) at 12 weeks This test will be used to assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors and sleep-related quality of life. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05582070 - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction N/A
Recruiting NCT03919955 - A Novel Pharmacological Therapy for Obstructive Sleep Apnea Phase 2
Completed NCT03927547 - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT01503164 - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism N/A
Recruiting NCT00747890 - Surgical Treatment of Mild Obstructive Sleep Apnea N/A
Active, not recruiting NCT00738179 - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease Phase 3
Completed NCT00841906 - Alice PDx User/Validation Extended Trial N/A
Completed NCT00202501 - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome N/A
Completed NCT00047463 - Effects of Treating Obstructive Sleep Apnea in Epilepsy Phase 2
Not yet recruiting NCT06029881 - Portable System for Non-intrusive Monitoring of Sleep
Recruiting NCT06093347 - Central Apnoea Monitor Study
Terminated NCT05445869 - Severe OSA Study (SOS) N/A
Withdrawn NCT04096261 - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Completed NCT04676191 - Validation of a Contactless Vital Signs Measurement Sensor N/A
Recruiting NCT06015620 - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed NCT06051097 - Metabolic Syndrome and Obstructive Sleep Apnea
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Recruiting NCT05197855 - Sleep Quality Evolution: Dreem Under CPAP N/A